美股異動 | 阿斯利康漲近6% Q4利潤超預期
格隆匯2月10日丨阿斯利康(AZN.US)漲5.76%,報68.07美元,總市值2109億美元。公司盤前公佈Q4業績顯示,儘管新冠疫苗銷售下滑,影響整體年減近一成,略低於華爾街分析師預期,不過在其癌症和罕病療法支撐下,淨利表現出色,打敗分析師預期(每股收益1.38美元,高於分析師平均預期的1.35美元)。另外,公司對前景展望樂觀,在開發新藥與現有藥物進展順利,有望實現2025年的增長目標並持續到2030年。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.